Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS)

Abstract

BackgroundSerrated or Hyperplastic Polyposis Syndrome (SPS, HPS) is a yet poorly defined colorectal cancer (CRC) predisposition characterised by the occurrence of multiple and/or large serrated polyps throughout the colon. A serrated polyp-CRC sequence (serrated pathway) of CRC formation has been postulated, however, to date only few molecular signatures of serrated neoplasia (BRAF, KRAS, RNF43 mutations, CpG Island Methylation, MSI) have been described in a subset of SPS patients and neither the etiology of the syndrome nor the distinct genetic alterations during tumorigenesis have been identified.MethodsTo identify somatic point mutations in potential novel candidate genes of SPS-associated lesions and the involved pathways we performed exome sequencing of eleven early serrated polyps obtained from a 41 year-old female patient with clinically confirmed SPS. For data filtering and analysis, standard pipelines were used. Somatic mutations were identified by comparison with leukocyte DNA and were validated by Sanger sequencing.ResultsThe BRAF p.V600E or KRAS p.G12D mutation was identified in six polyps (~50%) and not found in polyps from the distal colon. In addition, we found seven unique rare somatic alterations of seven different genes in four serrated tumours, all of which are missense variants. The variant in ABI3BP and CATSPERB are predicted to be deleterious. No established cancer gene or candidate genes related to serrated tumorigenesis were affected.ConclusionsSomatic mutations seem to be rare events in early hyperplastic and serrated lesions of SPS patients. Neither frequently affected genes nor enrichment of specific pathways were observed. Thus, other alterations such as non-coding variants or epigenetic changes might be the major driving force of tumour progression in SPS.Electronic supplementary materialThe online version of this article (10.1186/s13053-017-0082-9) contains supplementary material, which is available to authorized users.

Neoexpression of JUNO in Oral Tumors Is Accompanied with the Complete Suppression of Four Other Genes and Suggests the Application of New Biomarker Tools

“…CatsperB was found to be deleterious in colorectal cancer, namely serrated polyposis syndrome [ 21 ]. A pancancer multiomics analysis identified CatsperB as a potential protein partner of Tac2-N [ 22 ].…”

Automated Imaging Cytometry Reveals Dysplastic Indices of Colonic Serrated Adenomas

“…The relationship between HP and serrated adenomas is poorly understood, but given their similar DIs, our results suggest the involvement of the CIN pathway. Additionally, assessing for CIN in serrated or hyperplastic polyposis syndrome (SPS, HPS) samples could shed light onto the pathway of neoplastic progression for serrated polyposis syndrome and HPS and KRAS mutations have been implicated in both [37]. Nevertheless, larger follow-up studies are required to assess whether the patients with L-HP and L-SA demonstrating elevated DI indeed have higher neoplastic risks compared with those with normal DI.…”

Birt-Hogg-Dubé syndrome with simultaneous hyperplastic polyposis of the gastrointestinal tract: case report and review of the literature

“…Microscopically, hyperplastic polyps are defined by luminal and crypt serration with normal architecture and normal proliferative characteristics [12,13]. In the large intestine, these tumors are frequently detected in adults and the elderly [14] and may be solitary or multiple. They are usually smaller than 5 mm in diameter, are more frequent in the distal colon and rectum, and are usually asymptomatic.…”

“…They are usually smaller than 5 mm in diameter, are more frequent in the distal colon and rectum, and are usually asymptomatic. Most colorectal hyperplastic polyps have no malignant potential, but some may progress to colorectal carcinoma [14].…”